Velan Capital Investment Management’s Protara Therapeutics TARA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.8M Hold
2,834,652
9.25% 2
2025
Q4
$15.1M Buy
2,834,652
+695,652
+33% +$3.87M 8.76% 3
2025
Q3
$9.3M Hold
2,139,000
8.74% 3
2025
Q2
$6.48M Buy
2,139,000
+471,200
+28% +$1.63M 6.4% 4
2025
Q1
$7.1M Buy
1,667,800
+88,800
+6% +$397K 7.31% 4
2024
Q4
$8.34M Buy
1,579,000
+1,005,000
+175% +$3.25M 7.19% 5
2024
Q3
$1.05M Buy
574,000
+94,000
+20% +$193K 0.98% 14
2024
Q2
$998K Buy
+480,000
New +$1.4M 0.57% 14

Other funds holding TARA

Velan Capital Investment Management's TARA Position: Q1 2026 in Review

Velan Capital Investment Management held its Protara Therapeutics (TARA) position steady in Q1 2026 at 2,834,652 shares worth $14.8M. The position accounts for 9.25% of the portfolio, ranked #2.

Velan Capital Investment Management first reported a position in TARA in Q2 2024 and has held it in 8 quarters since. The position peaked at $15.1M in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Velan Capital Investment Management held 2,834,652 shares of Protara Therapeutics worth $14.8M as of Q1 2026.
  • Velan Capital Investment Management left its Protara Therapeutics share count unchanged in Q1 2026.
  • Protara Therapeutics made up 9.25% of Velan Capital Investment Management's portfolio in Q1 2026, its #2 holding.
  • Velan Capital Investment Management first reported a position in Protara Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Velan Capital Investment Management's Protara Therapeutics position peaked at $15.1M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.